Schlichtig K, Duerr P, Dörje F, Fromm M (2019)
Publication Type: Journal article, Review article
Publication year: 2019
Book Volume: 116
Pages Range: 775-+
Journal Issue: 46
DOI: 10.3238/arztebl.2019.0775
Background: Many oral anti-cancer drugs have come onto the market in the past 20 years. For example. kinase inhibitors, such as the BCR-ABL and BRAF inhibitors, have markedly improved the treatment of chronic myeloid leukemia and melanoma. In this review, we discuss the special challenges posed by poor adherence, drug-drug interactions with other substances, and side effects, among other problems, and the ways in which these challenges can be met.
APA:
Schlichtig, K., Duerr, P., Dörje, F., & Fromm, M. (2019). New Oral Anti-Cancer Drugs and Medication Safety. Deutsches Ärzteblatt international, 116(46), 775-+. https://doi.org/10.3238/arztebl.2019.0775
MLA:
Schlichtig, Katja, et al. "New Oral Anti-Cancer Drugs and Medication Safety." Deutsches Ärzteblatt international 116.46 (2019): 775-+.
BibTeX: Download